Toward Bridging Unmet Medical Need in Early Alzheimer’s Disease: An Evaluation of Beta‐Amyloid (Aβ) Plaque Burden as a Potential Drug Development Tool-Reference-Cited by-同舟云学术

Toward Bridging Unmet Medical Need in Early Alzheimer’s Disease: An Evaluation of Beta‐Amyloid (Aβ) Plaque Burden as a Potential Drug Development Tool

Published:2022-02-20 Issue:4 Volume:111 Page:728-731
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Zhu Hao¹,Mehta Mehul¹,Huang Shiew‐Mei¹,Wang Yaning¹

Affiliation:

1. Office of Clinical Pharmacology Office of Translational Sciences Center of Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2536

Reference8 articles.

1. Advisory Committee Meeting Package for Aducanumab Accessed June 8 2021.

2. Swanson C.J.et al. Clinical and Biomarker Updates from BAN2401 Study 201 in Early AD. Presented at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference Barcelona Spain October 24–27 2018.

3. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

4. Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

5. Bittner T.et al.Phase III Studies of Crenezumab in Early (Prodromal‐to‐Mild) Alzheimer’s Disease (CREAD/CREAD2): Biomarker Results. Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Conference San Diego California December 4–7 2019.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer’s disease;Med;2024-09

2. A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer’s Disease;The Journal of Prevention of Alzheimer's Disease;2024

3. Advancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review;International Journal of Alzheimer’s Disease;2024-01

4. Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes;Alzheimer's & Dementia;2023-12-25

5. Passive Immunotherapies Targeting Amyloid-βin Alzheimer’s Disease: A Quantitative Systems Pharmacology Perspective;Molecular Pharmacology;2023-10-31